Clinical Trial Detail

NCT ID	NCT02264678
Title	Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	triple-receptor negative breast cancer Her2-receptor negative breast cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma gastric adenocarcinoma lung adenocarcinoma lung non-small cell carcinoma ovarian cancer ovary epithelial cancer peritoneum cancer fallopian tube cancer Advanced Solid Tumor
Therapies	AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib
Age Groups:	senior adult